Efficacy of poloxamer 188 in aplastic anemia model induced by carboplatin in CBA mice

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The efficacy of poloxamer 188 on medullary hematopoiesis in aplastic anemia was investigated. The present study demonstrated that poloxamer 188 at doses of 10 mg/kg, 100 mg/kg and 500 mg/kg administered via oral gavage in CBA mice, in the context of the development of anemia, a dose-dependent effect was observed, characterized by an increase in erythrocyte, hemoglobin and reticulocyte numbers. In the group with carboplatin, these parameters were decreased on day 21, indicating mild anemia. It has been established that P188 has the capacity to exert a beneficial influence on the blood cell composition, which is disrupted by cytostatic drugs.

Full Text

Restricted Access

About the authors

A. V. Kholina

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Federal State Budgetary Educational Institution of Higher Education “Russian Biotechnological University (BIOTECH University)”

Email: borozdina@bibch.ru

Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Pushchino Branch of the Federal State Budgetary Educational Institution of Higher Education “Russian Biotechnological University (BIOTECH University)”

Russian Federation, Pushchino; Pushchino

V. A. Palikov

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Email: borozdina@bibch.ru

Branch

Russian Federation, Pushchino

N. A. Borozdina

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Author for correspondence.
Email: borozdina@bibch.ru

Branch

Russian Federation, Pushchino

I. N. Kravchenko

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Email: borozdina@bibch.ru

Branch

Russian Federation, Pushchino

I. A. Pakhomova

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Email: borozdina@bibch.ru

Branch

Russian Federation, Pushchino

R. A. Dalevich

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Federal State Budgetary Educational Institution of Higher Education “Russian Biotechnological University (BIOTECH University)”

Email: borozdina@bibch.ru

Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Pushchino Branch of the Federal State Budgetary Educational Institution of Higher Education “Russian Biotechnological University (BIOTECH University)”

Russian Federation, Pushchino; Pushchino

S. Z. Hajiguliyeva

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Email: borozdina@bibch.ru

Branch

Russian Federation, Pushchino

E. V. Arshintseva

Medical emulsions LLC

Email: borozdina@bibch.ru
Russian Federation, Serpukhov

S. Yu. Pushkin

Medical emulsions LLC

Email: borozdina@bibch.ru
Russian Federation, Serpukhov

I. A. Dyachenko

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Email: borozdina@bibch.ru

Branch

Russian Federation, Pushchino

A. N. Murashev

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Email: borozdina@bibch.ru

Branch

Russian Federation, Pushchino

References

  1. Chen W.N., Shaikh M.F., Bhuvanendran S., et al. Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review // Curr Neuropharmacol. 2022. Vol. 20, N4. P. 799–808.
  2. Ruhl T., Storti G., Pallua N. Proliferation, Metabolic Activity, and Adipogenic Differentiation of Human Preadipocytes Exposed to 2 Surfactants In Vitro // J Pharm Sci. 2018. Vol. 107, N5. P. 1408–1415.
  3. Moloughney J.G., Weisleder N. Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications // Recent Pat Biotechnol. 2012. Vol. 6, N3. P. 200–11.
  4. Zylke J. Poloxamer 188 for Sickle Cell Disease // JAMA. 2021. Vol. 325, N 15. P. 1524.
  5. Gibbs W.J., Hagemann T.M. Purified poloxamer 188 for sickle cell vaso-occlusive crisis // Ann Pharmacother. 2004. Vol. 38, N2. P. 320–324.
  6. Аршинцева Е.В., Пушкин С.Ю. Новое применение полоксамера в качестве фармакологически активного вещества. Патент РФ № 2 760 324. 2021.11.24.
  7. Moore C. A., Krishnan K. Aplastic Anemia. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
  8. Dygai A.M., Zyuz’kov G.N., Zhdanov V.V., et al. Mechanisms underlying modulation of the pharmacological properties of pegylated erythropoietin by pegylated hyaluronate-endo-β-N-acetylhexosaminidase // Bull Exp Biol Med. 2013. Vol. 154, N6. P. 750–4.
  9. BASF NA Product Regulations. Safety Data Sheet Kolliphor® P 188 Geismar; 2020.
  10. Wang J.B., Du M.W., Zheng Y. Effect of ginsenoside Rg1 on hematopoietic stem cells in treating aplastic anemia in mice via MAPK pathway // World J Stem Cells. 2024. Vol. 16, N5. P. 591–603.
  11. Sandor B., Marin M., Lapoumeroulie C., et al. Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia // Br J Haematol. 2016. Vol. 173, N1. P. 145–149.
  12. Crawford J., Herndon D., Gmitter K., et al. The impact of myelosuppression on quality of life of patients treated with chemotherapy // Future Oncol. 2024. P. 1–16.
  13. Zhang Y., Tang L., Sun L., et al. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment // Acta Biomater. 2010. Vol. 6, N6. P. 2045–2052.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russian Academy of Sciences